Nancy H. Agee, a director at Precigen, purchased 3,411 shares of the company’s common stock for $24,661 on August 21, 2026, according to a SEC Form 4 filing.
The transaction was executed at a price of $7.23 per share. Following the acquisition, Agee’s direct holdings in Precigen total 309,187 shares.
Precigen’s stock has delivered a 71% return over the past year, with shares trading near a 52-week high of $7.55. Analyst price targets for the stock range from $11 to $18, while InvestingPro assesses the current valuation as fair.
The company’s second-quarter financial performance contributed to investor confidence. Precigen reported earnings of $0.05 per share, exceeding expectations of a $0.01 loss, alongside revenue of $54.98 million—nearly double the analyst forecast of $27.83 million. Net income for the quarter reached $20.1 million, driven by strong demand for PAPZIMEOS, the firm’s approved therapy for adult recurrent respiratory papillomatosis.
